Dra. Anna Meseguer Anna Meseguer obtained her Degree in Biology from the Universitat Autònoma de Barcelona (UAB) and completed her PhD in Experimental Tumor Immunogenetics under the supervision of Professor Dr. Lloyd J. Old at the Memorial Sloan Kettering Cancer Center in New York City. She then became a postdoctoral fellow in the NIH Endocrinology Training Program in Medicine and subsequently secured a tenure-track position (Research Investigator II) at the Center for Biomedical Research at Rockefeller University (New York), where she investigated sex-hormone regulation of gene expression in the kidney.After eight years in New York, she co-founded the first Experimental Research Unit at the Vall d’Hebron campus and has led the Renal Physiopathology Group since October 1990. Dr. Meseguer has served as principal investigator and leader of numerous competitive national and international translational research projects (46), has published more than 82 peer-reviewed papers in high-impact journals, and has been deeply involved in training programs (supervising 25 PhD theses, 39 Master’s theses, and tutoring an additional 47 PhD theses). Dra. Anna Meseguer Anna Meseguer obtained her Degree in Biology from the Universitat Autònoma de Barcelona (UAB) and completed her PhD in Experimental Tumor Immunogenetics under the supervision of Professor Dr. Lloyd J. Old at the Memorial Sloan Kettering Cancer Center in New York City. She then became a postdoctoral fellow in the NIH Endocrinology Training Program in Medicine and subsequently secured a tenure-track position (Research Investigator II) at the Center for Biomedical Research at Rockefeller University (New York), where she investigated sex-hormone regulation of gene expression in the kidney.After eight years in New York, she co-founded the first Experimental Research Unit at the Vall d’Hebron campus and has led the Renal Physiopathology Group since October 1990. Dr. Meseguer has served as principal investigator and leader of numerous competitive national and international translational research projects (46), has published more than 82 peer-reviewed papers in high-impact journals, and has been deeply involved in training programs (supervising 25 PhD theses, 39 Master’s theses, and tutoring an additional 47 PhD theses).
Under her leadership, the group has held the Quality Mention from the Generalitat de Catalunya since 2005, maintaining a strong focus on translational research, particularly on the role of sex hormones in kidney injury and regeneration, hypertension, metabolism, cancer, and, over the past 12 years, rare kidney diseases, collaborating with patient association called Asdent and Hipofam. The group is also highly active in innovation, has obtained several patents, and contributed to the creation of the kidney gene therapy–oriented start-up NinevahTx. Among other distinctions, Dr. Meseguer received the Research Trajectory Award from the Col·legi de Biòlegs de Catalunya i Balears in 2019.She has been an Associate Professor in the Department of Biochemistry and Molecular Biology at the UAB Medical School and co-founder and coordinator of the Master’s Program in Translational Biomedical Research at the Vall d’Hebron Research Institute (VHIR/UAB). In 2009, she obtained a Master’s degree in Leadership and Management of Science and Innovation from the Barcelona School of Management. For six years, she also served as Associate Director for Basic and Translational Research at VHIR, as well as Secretary of the Internal Scientific Committee.From October 2019 to January 2022, she served as Head of Operations and Institutional Relations at the General Directorate of Science and Innovation (DGRIS) of the Catalan Ministry of Health. During this period, she led and coordinated the Pla Estratègic de Recerca i Innovació en Salut 2021–2025 and actively contributed to the strategic plans for the Instituts de Recerca i Innovació en Salut de Catalunya (IRISCAT) and the Pla de Salut 2021–2025 of the Generalitat de Catalunya. Additionally, she participated in COVID-19–related initiatives, including leading the COVID.CAT project and serving on the Expert Committee for the initiative Implantació del Programa d’Oncologia de Precisió en el Sistema Sanitari Públic de Catalunya (Servei Català de la Salut, Resolució Instrucció 03/2021), among other duties.These experiences have provided her with deep knowledge of the rich Catalan research and innovation ecosystem, its institutions, and its leadership.
